Trials / Completed
CompletedNCT00325351
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
Phase 1/2 Study of ZK-Epothilone (ZK-Epo; ZK-219477) in Combination With Carboplatin in Patients With Platinum-sensitive Recurrent Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Detailed description
This study has previously been registered by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is sponsoring this trial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sagopilone (ZK 219477) + carboplatin | Chemotherapy for recurrent ovarian cancer |
Timeline
- Start date
- 2006-08-24
- Primary completion
- 2008-07-08
- Completion
- 2009-03-25
- First posted
- 2006-05-12
- Last updated
- 2021-04-08
Locations
16 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00325351. Inclusion in this directory is not an endorsement.